News

Lilly Signs $1.3 Billion Deal to Discover Obesity Medicines Using AI

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...
Zacks Investment Research on MSN6h

Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?

Novo Nordisk NVO recently underwent a major leadership transition, as Lars Fruergaard Jørgensen stepped down as CEO on Aug. 7 ...

Rival fat jab WON’T increase in price, makers pledge – as Mounjaro set to double in costs

MAKERS of the fat jab Wegovy say they will not increase the price of the drug when the cost of rival Mounjaro doubles next ...
Medical Dialogues10h

Novo Nordisk Launches Wegovy in South Africa, Ramping Up Obesity Drug Battle with Eli Lilly

Johannesberg: Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's ...

Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...
Bizcommunity on MSN20h

Danish weight-loss drug Wegovy debuts in South Africa, challenging Eli Lilly

Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa, marking its debut in Africa and ...